Literature DB >> 16199787

Cannabis use and misuse prevalence among people with psychosis.

Bob Green1, Ross Young, David Kavanagh.   

Abstract

BACKGROUND: Increasing attention has been given by researchers to cannabis use in individuals with psychosis. As psychoses are relatively low-prevalence disorders, research has been mostly been restricted to small-scale studies of treatment samples. The reported prevalence estimates obtained from these studies vary widely. AIMS: To provide prevalence estimates based on larger samples and to examine sources of variability in prevalence estimates across studies.
METHOD: Data from 53 studies of treatment samples and 5 epidemiological studies were analysed.
RESULTS: Based on treatment sample data, prevalence estimates were calculated for current use (23.0%), current misuse (11.3%), 12-month use (29.2%), 12-month misuse (18.8%), lifetime use (42.1%) and lifetime misuse (22.5%). Epidemiological studies consistently reported higher cannabis use and misuse prevalence in people with psychosis.
CONCLUSIONS: The factor most consistently associated with increased odds of cannabis prevalence was specificity of diagnosis. Factors such as consumption patterns and study design merit further consideration.

Entities:  

Mesh:

Year:  2005        PMID: 16199787     DOI: 10.1192/bjp.187.4.306

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  42 in total

Review 1.  Clinical staging in the pathophysiology of psychotic and affective disorders: facilitation of prognosis and treatment.

Authors:  Trevor Archer; Richard M Kostrzewa; Tomas Palomo; Richard J Beninger
Journal:  Neurotox Res       Date:  2010-03-17       Impact factor: 3.911

2.  Genetic and Environmental Contributions to the Association Between Cannabis Use and Psychotic-Like Experiences in Young Adult Twins.

Authors:  Ragnar Nesvåg; Ted Reichborn-Kjennerud; Nathan A Gillespie; Gun Peggy Knudsen; Jørgen G Bramness; Kenneth S Kendler; Eivind Ystrom
Journal:  Schizophr Bull       Date:  2017-05-01       Impact factor: 9.306

Review 3.  The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.

Authors:  Britta Hahn
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

4.  Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization.

Authors:  Daniel J Foti; Roman Kotov; Lin T Guey; Evelyn J Bromet
Journal:  Am J Psychiatry       Date:  2010-05-17       Impact factor: 18.112

5.  Genetic predisposition to schizophrenia associated with increased use of cannabis.

Authors:  R A Power; K J H Verweij; M Zuhair; G W Montgomery; A K Henders; A C Heath; P A F Madden; S E Medland; N R Wray; N G Martin
Journal:  Mol Psychiatry       Date:  2014-06-24       Impact factor: 15.992

6.  Astrocytic Mechanisms Involving Kynurenic Acid Control Δ9-Tetrahydrocannabinol-Induced Increases in Glutamate Release in Brain Reward-Processing Areas.

Authors:  Maria E Secci; Paola Mascia; Claudia Sagheddu; Sarah Beggiato; Miriam Melis; Andrea C Borelli; Maria C Tomasini; Leigh V Panlilio; Charles W Schindler; Gianluigi Tanda; Sergi Ferré; Charles W Bradberry; Luca Ferraro; Marco Pistis; Steven R Goldberg; Robert Schwarcz; Zuzana Justinova
Journal:  Mol Neurobiol       Date:  2018-08-27       Impact factor: 5.590

Review 7.  Cannabis regulatory science: risk-benefit considerations for mental disorders.

Authors:  Jacob T Borodovsky; Alan J Budney
Journal:  Int Rev Psychiatry       Date:  2018-05-29

Review 8.  Treatment of substance abusing patients with comorbid psychiatric disorders.

Authors:  Thomas M Kelly; Dennis C Daley; Antoine B Douaihy
Journal:  Addict Behav       Date:  2011-09-14       Impact factor: 3.913

Review 9.  Research in people with psychosis risk syndrome: a review of the current evidence and future directions.

Authors:  Christoph U Correll; Marta Hauser; Andrea M Auther; Barbara A Cornblatt
Journal:  J Child Psychol Psychiatry       Date:  2010-02-26       Impact factor: 8.982

10.  Should burden of disease estimates include cannabis use as a risk factor for psychosis?

Authors:  Louisa Degenhardt; Wayne D Hall; Michael Lynskey; John McGrath; Jennifer McLaren; Bianca Calabria; Harvey Whiteford; Theo Vos
Journal:  PLoS Med       Date:  2009-09-29       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.